Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8542283 | 0.81 | ALOX5 (0.46) | ALOX5ALDH1A1HTR1ATSHR | |
| SCHEMBL15326776 | 0.80 | ALOX5 (0.50) | ALOX5LMNAALDH1A1HTR1A | |
| SCHEMBL12309926 | 0.77 | ALOX5 (0.35) | ALOX5LMNACA1CA2TRPA1 | |
| SCHEMBL22150042 | 0.77 | ALOX5 (0.47) | ALOX5ALDH1A1HTR1A | |
| SCHEMBL18896365 | 0.77 | LMNA (0.32) | ALOX5LMNACA1CA2TRPA1 | |
| SCHEMBL1856684 | 0.77 | ALOX5 (0.43) | ALOX5ALDH1A1HTR1A | |
| SCHEMBL7326998 | 0.77 | ALOX5 (0.47) | ALOX5ALDH1A1HTR1A | |
| SCHEMBL21064027 | 0.77 | ALOX5 (0.43) | ALOX5ALDH1A1 | |
| SCHEMBL21142354 | 0.77 | ALOX5 (0.43) | ALOX5HTR1ATSHR | |
| SCHEMBL178626 | 0.77 | ALOX5 (0.43) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024086814-A2 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230167139-A1 | PHOTOCHROMIC GERMOLE-FUSED DIARYLETHENES AND PRODUCTION THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230167139-A1 | PHOTOCHROMIC GERMOLE-FUSED DIARYLETHENES AND PRODUCTION THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2023-06-01 | — | — | US | disclosed |
| US-11634445-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-08 | — | — | US | disclosed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| WO-2008063669-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | RNASE1, GTF3C3, CTRL | ALOX5 4509/4885LMNA 2842/4885CA1 4225/4885 |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | EIF2AK2, ZC3HAV1, MAVS | ALOX5 3857/4885LMNA 1404/4885CA1 4504/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | ALOX5 1243/4885LMNA 2478/4885CA1 325/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | ALOX5 4073/4885LMNA 4600/4885CA1 3634/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | ALOX5 2402/4885LMNA 671/4885CA1 3411/4885 |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | IL4, IL2, IL4I1 | ALOX5 2099/4885LMNA 4868/4885CA1 4502/4885 |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ALOX5 2070/4885LMNA 4785/4885CA1 4883/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ALOX5 2070/4885LMNA 4785/4885CA1 4883/4885 |
| US-20230167139-A1 | PHOTOCHROMIC GERMOLE-FUSED DIARYLETHENES AND PRODUCTION THEREOF | AGL, GMNN, GAK | ALOX5 2920/4885LMNA 1450/4885CA1 4315/4885 |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | ALOX5 135/4885LMNA 4871/4885CA1 3904/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | ALOX5 2975/4885LMNA 2203/4885CA1 3820/4885 |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | ALOX5 1245/4885LMNA 2524/4885CA1 334/4885 |
| US-11634445-B2 | Organic electroluminescent materials and devices | L1CAM, EPCAM, SOD1 | ALOX5 3209/4885LMNA 731/4885CA1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.